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1. Introduction 
Endonuclease IV, the minor Escherichia coli 
endonuclease pecific for apurinic sites, has been 
shown [ 1) to be active on apyrimidinic sites produced 
by uracil-DNA glycosylase. It was of interest o 
investigate whether the rat liver enzyme was also 
active on apyrimidinic sites. However, we have used 
an Al? endodeoxy~bonuclease (i. ., an endonuclease 
specific for apu~nic and apyr~idi~ic sites in DNA) 
to analyze the products of the reaction of DNA with 
chemical agents uch as hydrazine and bleomycin. 
Bleomycin, a glycopeptide with mol. wt of - 1500, 
is an antibiotic produced by Streptomyces verticillus, 
isolated [2,3] . The action of the drug on DNA 
strongly depends on its concentration. At high con- 
centrations, the four bases are removed from DNA 
[4] and double-strand as well as single-strand breaks 
are produced [S] . But, at low concentrations, 
bleomycin splits off mostly thymine bases [6] and 
the possibly of interc~ation of one of the thiazole 
rings of the antibiotic in the double-held at the place 
of the lost pyrimidine has been suggested [ 71. Because 
bleomycin is currently used in the chemotherapy of
neoplastic diseases [&-lo] , the problem of the repair 
of DNA lesions produced by this agent is important; 
we wanted particularly to know whether the base-free 
sites were accessible to a repair endodeoxyribo- 
nuclease. 
2. Materials and methods 
Labelled E. co2i DNA is prepared in the presence of 
[met&+3H] thymidine; it has a specific radioactivity 
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of 60 300 dpm/pg and is kept in 0.15 M NaCl, 
0.015 M Na citrate, pH 7.0 (NaCl/cit.) at -30°C. 
2.1. Alkylated-depurinated / ‘H]DNA 
Alkylation with methyl methanesulfonate followed 
by heat-depurination has been described [ 111. The 
treated J3H)DNA kept in NaCljcit., 0.01 M MgCls , 
contains 160 apurinic sites and 390 methylated sites/ 
lo6 daltons; less than 1% is soluble in 5% perchloric 
acid, but NaOH trea~ent raises the acid-soluble 
fraction to 35%. 
2.2. Hydrazine-treated i3 HJDNA 
To 1 ml NaCl/cit. containing 375 l(g [3H]DNA are 
added 1.7 g hydrazine hydrochloride; it is adjusted to 
pH 7 with NaOH and brought o 2 ml with NaCl/cit. 
After 45 h at 37’C, the solution is dialyzed 3 times 
against NaCl/cit. at 0°C before addition of 0.7 ml 
10% sulfonated benzaldehyde inNaCl/cit. The solution 
(4.2 ml; pH 7) is kept for 4 h at room temperature, 
then dialyzed 3 times against NaCllcit., 0.01 M MgCl,. 
The treatment reduces the specific radioactivity of 
the DNA to 40 000 dpm/gg; < 1% is soluble in 5% 
perchloric acid, but NaOH treatment raises the acid- 
soluble fraction to 5%. 
2.3. Bleomycin-treatment (‘H]DNA 
A thiol is necessary for the rapid release of 
[3H]thymine from the labelled DNA by the antibiotic 
and the reaction rate at pH 8.2 is far from negligible 
at 0°C; but the reaction decreases drastically below 
pH 7.3, the pK, of the amine group of the amino- 
alanine (fig. 1). 
To 0.85 ml NaCllcit. containing 320 &g 13H]DNA 
are added 1 ml of 0.1 M Tris. HCl, 0.02 M dithio- 
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Fig.1. Effect of pH on the release by bleomycin of dialysable 
radioactivity from DNA labelled in thymine moieties. 400 ~1 
0.1 M Tris.HCl buffer adjusted at the indicated pH (abscissae) 
containing 0.020 M dithiothreitol, 4 ug bleomycin and 16 ng 
[ ‘H]DNA are incubated for 2 h at 37°C; the reaction is stopped 
by lowering to pH 6.5. The solution is dialyzed at O’C 
through a cellulose membrane in a two-compartment lucite 
apparatus; the radioactivity/ml dialysate is multiplied by the 
total apparatus olution volume and the result expressed in 
% substrate DNA radioactivity. Thin-layer chromatography 
has shown that the radioactivity of the dialysate is only in 
thymine molecules. 
threitol, pH 8.2, containing 200 pg bleomycin 
(Blenoxane, Bristol Laboratory, Syracuse, New York). 
After 4 h at 37°C the reaction is stopped by addition 
of cold 0.1 M citric acid, 0.2 M Naz HIQ, pH 5.9 
buffer, which lowers the pH to 6.5. The solution is 
then dialyzed at 0°C 3 times against NaCl/cit., 0.01 M 
MgClz. The treatment reduces the specific radio- 
activity of the DNA to 43 000 dpm/pg; 5% is soluble 
in 5% perchloric acid and NaOH treatment raises the 
acid-soluble fraction to 10%. 
2.4. NaOH treatment 
To 20 ~1 DNA solution containing - 20 pg/ml are 
added 20 ~10.4 M NaOH; after 15 min at 37’C, the 
mixture is neutralized with 20 ~10.4 M HCl. This 
treatment hydrolyses a phosphoester bond near each 
base-free site [ 1 l] . The characterization of the alkali- 
labile sites is however done at a lower pH (PH 12; see 
section 3). 
2.5. Determination of acid-soluble fraction 
To 60 /.11 [‘H]DNA solution are added 100 ~1 
NaCl/cit. containing 200 pg calf thymus DNA and 
900 ~15.9% cold perchloric acid. After shaking, the 
tubes are kept 15 min at 0°C centrifuged at 
13 000 X g for 15 min, and an aliquot of the super- 
natant assayed for radioactivity. 
2.6. Rat liver endonuclease specific for apurinic sites 
We followed the purification method in [ 121 
except that the phosphocellulose has been replaced 
by an affinity chromatography on DNA-Sepharose. 
The active fractions, dialyzed against 0.05 M Tris.HCl, 
0.1 mM EDTA, 0.1 mM dithiothreitol, pH 8, are 
mixed with an equal volume of glycerol and kept at 
--50°C. The preparation is without action on normal 
DNA strands and on alkylated sites; it is devoid of 
exonuclease activity. The enzyme unit is that used in 
P31. 
3. Results and discussion 
3.1. Hydrolysisrateof the treated[jH]DNAs at pH 12 
We have used the rate of appearance of acid-soluble 
radioactivity (which is nearly proportional to the rate 
of formation of strand breaks) at pH 12 and 37’C to 
characterize the alkali-labile sites. With the alkylated- 
depurinated DNA, the reaction is first order and the 
half-life of the alkali-labile sites is 37 min. Reaction 
of DNA with hydrazine only leaves several kinds of 
alkali-labile sites with different half-lives, but, after 
an additional treatment with the sulfonated benzal- 
dehyde, there remains only one kind of alkali-labile 
sites with the same half-life as the apurinic sites. The 
alkali-labile sites of the bleomycin-treated [3H]DNA 
also have the same half-life as the apurinic sites. 
3.2. Action of rat liver endonuclease specific for 
apurinic sites on the three substrates 
20 ~10.02 M Tris.HCl, 0.01 M MgClz, pH 8.0, 
containing 0.4 ,ug modified [3H]DNA and 20 ~.tl 
enzyme (7 units) in Tris.HCl, 0.01 M MgClz , are 
incubated at 37’C for various times before measuring 
the acid-soluble radioactivity; the results are corrected 
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Fig.2. Action of rat liver endonuclease specific for apurinic 
sites on alkylated-depurinated DNA and bleomycin-treated 
DNA. The experimental conditions are described in the 
text. The function ln(N,, -N) is given versus time, where N,, 
is the maximum acid-soluble radioactivity obtained when the 
incubation exceeds 10 min and N the acid-soluble radioactivity 
at the indicated time (mm). The best straight lines were 
determined by the least squares method and their slopes used 
to calculate the half-lives of the sensitive sites. 
for controls without enzyme. The enzyme being in 
large excess, the reaction follows first order kinetics 
with a half-life of 103 + 35 s for the alkylated- 
depurinated [‘H]DNA and 95 f 14 s for the bleo- 
my&r-treated [‘H]DNA (fig.2). In both cases, treat- 
ment with NaOH after the incubation with the 
enzyme yields the same acid-soluble radioactivity as 
treatment with NaOH alone showing that the reac- 
tive sites are the same for the alkali and the endo- 
nculease specific for apurinic sites. By contrast, the 
alkali-labile sites in the [3H]DNA treated successively 
with hydrazine and benzaldehyde are insensitive to 
the enzyme. 
Several conclusions can be drawn from these 
results: 
1. Treatment of DNA with bleomycin leads to a loss 
of thymine and the appearance of alkali-labile 
sites; because these alkali-labile sites are sensitive 
2. 
3. 
4. 
to the rat liver endonuclease pecific for apurinic 
sites, we conclude that this enzyme is also active 
on apyrimidinic sites. The enzyme is thus an AP 
endodeoxyribonuclease. 
Since the enzymic reaction rate on alkali-labile 
sites appears not to be different for the bleomycin- 
treated DNA and for the depurinated DNA, it is 
unlikely that, in our experimental conditions, the 
antibiotic remained intercalated in the double- 
helix replacing the departed thymine; such a 
situation would most probably prevent or at least 
decrease the activity of the endonuclease. The 
results also suggest that the base-free sites produced 
by bleomycin can be repaired. 
The reaction rates being the same on depurinated 
and depyrimidinated DNAs, it appears that the 
nature of the base (purine or pyrimidine) on the 
complementary DNA strand in front of the base- 
free site has no influence on the enzyme activity. 
There exist alkali-labile sites insensitive to the AP 
endodeoxyribonuclease  those in DNA treated 
successively with hydrazine and sulfonated benzal- 
dehyde. It is possible that there is no free aldehyde 
at the deoxyribose C-l’ of these alkali-labile sites; 
the substituent must however be quickly lost at 
pH 12 since it does not influence the rate of 
appearance of breaks near the alkali-labile sites at 
this pH. 
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